Last updated: February 24, 2026
What Is NDC 70436-0039?
NDC 70436-0039 refers to Aflibercept Injection, 2 mg/0.05 mL, marketed under the brand name Eylea. It is an anti-VEGF agent used primarily for treating age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular conditions.
Market Overview
Market Size and Growth
The global ophthalmic drugs market, driven by the demand for treatments for retinal diseases, stands at approximately USD 8.1 billion in 2022. Eylea holds a dominant position, accounting for about 50% of the anti-VEGF segment.
- 2018-2022 CAGR: 7.5% for ophthalmic anti-VEGF therapies.
- Indication Expansion: Eylea received approvals for indications such as diabetic retinopathy and myopic choroidal neovascularization, broadening active patient pools.
Key Competitors
| Drug |
Market Share (2022) |
Price Range (per dose) |
Approved Indications |
| Eylea (Aflibercept) |
~50% |
USD 1,850 – USD 2,100 |
AMD, DME, RVO, diabetic retinopathy |
| Lucentis (Ranibizumab) |
~35% |
USD 1,950 – USD 2,200 |
AMD, DME, RVO, diabetic retinopathy |
| Beovu (Brolucizumab) |
~10% |
USD 1,600 – USD 1,800 |
AMD |
| Others |
~5% |
Varies |
Off-label uses, biosimilars |
Revenue and Sales Trends
Eylea generated approximately USD 4.2 billion worldwide in 2022. Sales have seen a compound annual growth rate (CAGR) of 8% since 2018, driven by expanded indications and increased diagnosis rates.
Manufacturing and Distribution
Bayer manufactures Eylea. Distribution contracts exist globally, with USA and Europe accounting for about 70% of revenue.
Price Dynamics and Factors
Historical Pricing Trends
- Per-injection price for Eylea has ranged between USD 1,850 and USD 2,100 in the US.
- Pricing varies by payer type, with higher prices for private insurance compared to Medicare or Medicaid.
Reimbursement Environment
Medicare pricing adjustments and patent litigation influence net pricing. The introduction of biosimilars could impact Eylea pricing over the next five years.
Price Projections (Next 5 Years)
| Year |
Projected Average Price per Dose |
Key Drivers |
| 2023 |
USD 2,050 |
Stable demand, no biosimilar competition |
| 2024 |
USD 2,000 |
Entry of biosimilars, increased competition |
| 2025 |
USD 1,950 |
Biosimilar market penetration, payer negotiations |
| 2026 |
USD 1,900 |
Patent expirations in select markets, cost pressure |
| 2027 |
USD 1,850 |
Expanded biosimilar options, price erosion continues |
Pricing declines reflect biosimilar uptake, payer negotiations, and patent cliff effects.
Patent and Regulatory Landscape
- Patent expiry for Eylea's composition of matter is expected around 2023 in the United States.
- Regulatory approvals in emerging markets expand patient access, but price sensitivity varies by region.
Opportunities and Risks
Opportunities:
- Expanded labeling and new indications could increase patient volume.
- Biosimilar emergence could reduce costs and foster market share shifts.
Risks:
- Patent litigation delays.
- Changes in reimbursement policies.
- New therapies with longer durability may reduce injection frequency.
Key Takeaways
- Eylea (NDC 70436-0039) dominates the anti-VEGF market for retinal diseases with high revenues.
- Pricing has remained relatively stable but faces downward pressure due to biosimilar competition and patent expirations.
- The global market is expected to see declines in per-dose prices by up to 10% over five years, driven by biosimilar entries and market saturation.
- Growth will depend on regulatory approvals, new indications, and evolving payer policies.
FAQs
Q1: When will biosimilars for Eylea become available?
Expected entry in the US market around 2024-2025, after patent expiry and approval processes.
Q2: How will biosimilars impact Eylea pricing?
They will likely reduce prices by 15-30%, increasing competition and potentially lowering overall market revenues.
Q3: Are there upcoming regulatory changes affecting pricing?
Yes, adjustments in Medicare and Medicaid reimbursement policies may influence net prices.
Q4: What is the projected market share for Eylea in 2027?
It could decline to approximately 40-45% if biosimilar penetration is high and new treatments emerge.
Q5: Which regions pose the greatest growth opportunities?
Emerging markets such as China, India, and Latin America show potential for expanding access and sales.
References
- MarketResearch.com. (2022). Ophthalmic Drugs Market Size & Trends. Retrieved from https://www.marketresearch.com
- IQVIA. (2022). Global Ophthalmic Drugs Sales Data.
- Bayer. (2022). Eylea Product Monograph.
- U.S. Food & Drug Administration. (2022). Approved Biologics.
- Evaluating the impact of biosimilar entry (2021). Journal of Ophthalmology.
